Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 9/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501964 | 0.81 | RCE1 (0.40) | ROCK2RCE1HRH3 | |
| SCHEMBL5961474 | 0.80 | PIM3 (0.40) | ROCK2RCE1CHEK1 | |
| SCHEMBL6502700 | 0.74 | CCR2 (0.63) | — | |
| SCHEMBL5961485 | 0.74 | RCE1 (0.50) | RCE1 | |
| Hydrochloric Acid SCHEMBL6502089 | 0.74 | CCR2 (0.64) | — | |
| SCHEMBL6503802 | 0.74 | CCR2 (0.62) | — | |
| Hydrochloric Acid SCHEMBL6503076 | 0.73 | CCR2 (0.63) | — | |
| SCHEMBL5961519 | 0.72 | RCE1 (0.48) | ROCK2RCE1 | |
| SCHEMBL6504815 | 0.70 | CCR2 (0.62) | HRH3 | |
| SCHEMBL14334591 | 0.69 | DRD2 (0.50) | BCHEACHEPARP1DHODHCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962926-B2 | Antagonist of MCP-1 function, and compositions and methods of use thereof | TELIK, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | CCR1, CCL11, CCL2 | BCHE 1177/4885ACHE 704/4885PARP1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.